Why biosimilars are changing the pharmaceutical industry
07 June 2017
We caught up with Celltrion Healthcare‘s Ho-ung Kim to find out how biosimilars cut costs, increase access to medicine and are ultimately changing the industry…
Drug Prices Become Target for FDA as Chief Expands Purview
06 June 2017
The head of the U.S. Food and Drug Administration is considering using the agency’s powers to bring more price competition to the market for generic drugs, targeting high-priced products by prioritizing the approval of additional competing treatments.
06 June 2017
On May 31, 2017, the European Medicines Agency (EMA) and the European Commission published guidance on how pharmaceutical companies can prepare for Brexit. The guidance offers information on centralized procedures and other agency activities. The guidance is one in a series of guidance documents the agency plans to publish on the effects of the United Kingdom’s withdrawal from the European Union.
05 June 2017
Over the last few months it hasn’t been unusual to see new combination studies being announced on a daily basis, matching one of the 5 approved PD-(L)1 checkpoint drugs with another cancer therapy. Some mornings they come in pairs.
Investments in the new Russian plant will reach 5.3 billion rubles
05 June 2017
The investments in Pharmoslavl, the plant for manufacturing the active pharmaceutical substances, which will be launched in the Yaroslavl region before the end of 2017, will amount to 5.3 billion rubles. This was announced at the St. Petersburg Economic Forum (SPIEF) by Dmitry Mironov, the acting Governor of Yaroslavl region.
02 June 2017
NovaDigm Therapeutics, a company developing innovative immunotherapeutics and preventative vaccines for fungal and bacterial infections, today announced awards totaling $6 million from the U.S. Department of Defense to conduct a clinical study of NDV-3A in military personnel at high risk for skin and soft tissue infections due to Staphylococcus aureus (“S. aureus”), including methicillin-resistant S. aureus (MRSA). NovaDigm will collaborate with the Uniformed Services University of the Health Sciences (USU) on the execution of the Phase 2a study among U.S. Army Infantry trainees at Fort Benning, GA.
New report heralds a revolution in cancer R&D trends – and the sticker shock that comes with it
02 June 2017
There’s a revolution playing out in cancer R&D. Over the last decade drug developers focused on oncology have teamed with regulators on designing a shorter R&D path for new cancer drugs, using trial designs that have sped clinical work and slashed the number of patients needed to demonstrate safety and efficacy.
Drugmakers Brace for Trump's Proposals to Tackle U.S. Prices
01 June 2017
Two top pharmaceutical CEOs say they expect President Donald Trump, a frequent critic of industry pricing practices, to take steps soon to address high U.S. drug costs.
Pfizer bows first Ibrance TV spot as Novartis revs up with rival breast cancer med Kisqali
30 May 2017
Pfizer has launched its first TV ad for breast cancer drug Ibrance, joining a larger mainstream push for cancer drugs in TV ads and coming hot on the heels of the FDA approval of Novartis' first-ever in-class competitor.
FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson
29 May 2017
Pfizer’s biosimilar to blockbuster anemia meds Epogen and Procrit won the support of an FDA expert panel on Thursday, moving another step closer to a potential approval.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia has expanded the mandatory health insurance program for 2024-2026
29 March 2024
Russian scientists have developed new TB vaccines for both injection and nasal administration.
29 March 2024
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024